Galen Medical Journal · 2026 · Volume 15 · e4153
Review Article

Lifestyle Modification and Bariatric Surgery in Type 2 Diabetes Remission

Running title: Diabetes Remission Strategies in T2DM

Noor AlFahhad1

1 Department of Family Medicine, College of Medicine, Qassim University, Buraidah, Saudia Arabia

Received2025-07-29
Revised2026-04-28
Accepted2026-06-13

DOI: 10.31661/gmj.v15i0.4153

Correspondence

Noor AlFahhad
Department of Family Medicine, College of Medicine, Qassim University, Buraidah, Saudia Arabia
Email: n.alfahhad@qu.edu.sa
Telephone: +966 58 144 6107

Abstract

Type 2 diabetes mellitus (T2DM) has traditionally been regarded as a chronic and progressively worsening disease. This paradigm is now challenged by evidence showing that remission is achievable in selected patients, particularly when interventions produce substantial and sustained weight loss. This narrative review synthesizes current evidence on lifestyle modification and bariatric/metabolic surgery as remission-inducing strategies, with emphasis on mechanisms, comparative efficacy, predictors of response, and limitations. Intensive lifestyle interventions, especially very-low-calorie diets and total diet replacement programs, can induce normoglycemia in selected individuals through reductions in hepatic and pancreatic fat, improved insulin sensitivity, and partial recovery of β-cell function. However, durability is limited and depends strongly on sustained weight loss. Bariatric/metabolic surgery, particularly Roux-en-Y gastric bypass and sleeve gastrectomy, achieves higher and more durable remission rates than non-surgical approaches. These effects are mediated by both weight loss and weight-independent mechanisms, including enhanced incretin signaling, altered bile acid metabolism, and gut microbiota changes. Consistent predictors of remission include shorter diabetes duration, lower baseline HbA1c, reduced treatment burden, greater weight loss, and preserved β-cell function. Despite these advances, relapse remains common, long-term randomized data are limited, and important barriers persist, including procedural risk, cost, and inequitable access. Overall, the evidence supports a shift from a model of inevitable progression toward one of potentially reversible metabolic dysfunction, with important implications for early, remission-oriented care.

Keywords: Type 2 Diabetes Mellitus Bariatric Surgery Diabetes Remission Lifestyle Modification Weight Loss

Introduction

Type 2 diabetes mellitus (T2DM) is a leading global cause of morbidity, mortality, and healthcare expenditure, with prevalence projected to exceed 1.3 billion cases by 2050 [1, 2]. The economic burden is substantial, accounting for approximately 1.7-1.8% of global gross domestic product and continuing to rise [3]. Despite this scale, the dominant clinical paradigm has remained largely unchanged. T2DM is typically managed as a chronic, progressive disease requiring stepwise intensification of pharmacotherapy [4]. Evidence from intensive dietary interventions and bariatric/ metabolic surgery demonstrates that normoglycemia can be restored and β-cell function can partially recover in a substantial proportion of patients [5-7].

These findings challenge the assumption of irreversible β-cell failure and support a model in which T2DM reflects potentially reversible metabolic dysfunction, particularly in earlier disease stages [6, 7]. An international consensus defines remission as HbA1c <48 mmol/mol (6.5%) for at least 3 months without glucose-lowering medication, while emphasizing uncertainties regarding durability and long-term risk [8, 9]. Remission remains uncommon in routine clinical care, reflecting both biological constraints and implementation barriers [10]. Substantial weight loss is central to remission because it reduces ectopic fat, restores insulin sensitivity, and improves β-cell function [11].

Lifestyle intervention and bariatric/metabolic surgery both target these pathways, but they differ markedly in magnitude, durability, and scalability of effect [12, 13]. This review focuses on mechanisms, comparative efficacy, predictors of success, and key limitations, with the aim of clarifying how remission-oriented care can be integrated into contemporary diabetes management.

Pathophysiology of T2DM

T2DM arises from the interaction between insulin resistance and progressive β-cell dysfunction, driven primarily by chronic energy excess and ectopic lipid deposition [4, 14].

Insulin Resistance

Insulin resistance in the liver, skeletal muscle, and adipose tissue is an early and central abnormality. Hepatic insulin resistance impairs suppression of gluconeogenesis, increasing fasting glucose, while reduced peripheral glucose uptake contributes to postprandial hyperglycemia [4, 15]. A major mechanistic driver is ectopic lipid accumulation, particularly diacylglycerols and ceramides, which disrupt intracellular insulin signaling pathways. This indicates that metabolic dysfunction is driven less by total adiposity than by lipid distribution and organ-specific fat deposition [16, 17].

β-Cell Dysfunction

Progression to overt diabetes occurs when pancreatic β-cells can no longer compensate for insulin resistance. This failure is mediated by chronic exposure to elevated glucose and fatty acids, leading to glucotoxicity, lipotoxicity, oxidative stress, and endoplasmic reticulum stress [15, 17]. Ectopic pancreatic fat further impairs insulin secretion and is strongly associated with diabetes risk, supporting a lipotoxic contribution to β-cell dysfunction [16, 18].

Ectopic fat and the twin‑cycle hypothesis

The twin-cycle hypothesis provides a unifying framework linking hepatic and pancreatic fat accumulation to T2DM pathogenesis [17, 18]. Excess caloric intake promotes hepatic fat accumulation, driving insulin resistance and increased hepatic glucose output. Compensatory hyperinsulinemia further enhances hepatic lipogenesis, creating a self-reinforcing cycle [19, 20]. In parallel, lipid accumulation in the pancreas impairs β-cell function, ultimately leading to hyperglycemia and clinical diabetes [17, 21].

Definitions and Criteria for Diabetes Remission

Definitions of T2DM remission have evolved substantially, reflecting a shift from complex, multi-tiered classifications toward a pragmatic and clinically applicable framework [9, 22]. Earlier consensus statements distinguished between partial, complete, and prolonged remission using different glycemic thresholds and duration criteria [22]. Although conceptually rigorous, this approach was difficult to apply consistently across clinical and research settings [8]. The current international consensus defines remission as HbA1c <48 mmol/mol (<6.5%) for at least 3 months in the absence of glucose-lowering therapy [8, 9, 22].

This definition prioritizes feasibility and standardization, facilitating comparison across studies and implementation in routine care [22]. The current definition does not capture heterogeneity in underlying disease biology, nor does it account for relapse risk or long-term metabolic health [8]. In particular, reliance on a single glycemic threshold may obscure clinically meaningful differences between transient glycemic improvement and durable disease modification [8, 9]. Furthermore, variability in definitions across earlier studies continues to complicate interpretation of remission rates and long-term outcomes [9]. This heterogeneity limits comparability between interventions and may lead to overestimation of durable remission [8].

Lifestyle Interventions for T2DM Remission

Lifestyle intervention is a primary strategy for achieving T2DM remission, with the magnitude and durability of weight loss emerging as the dominant determinants of success. However, outcomes vary substantially according to intervention intensity, adherence, and long-term maintenance [23].

Weight Loss Interventions

Clinically meaningful weight reduction, typically ≥10-15 kg, is the most consistent pre-dictor of remission, primarily through reduction of hepatic and pancreatic fat, restoration of insulin sensitivity, and recovery of β-cell function [11, 24]. The DiRECT trial established a clear dose-response relationship between weight loss and remission [25]. A structured primary care-led program incorporating total diet replacement achieved remission in 46% of participants at 12 months and 36% at 2 years, with substantially higher rates among those maintaining ≥10 kg weight loss [24, 25]. Longer-term follow-up demonstrates attenuation over time but sustained benefit relative to usual care [26].

Replication in real-world settings, including DiRECT-Australia and the NHS Path to Remission program, confirms the effectiveness of total diet replacement-based interventions, although lower remission rates reflect reduced adherence and implementation variability [27, 28]. These findings reinforce weight loss as the principal mechanism underlying remission while highlighting the challenge of long-term maintenance [28, 29].

Dietary Strategies: Efficacy and Limitations

A range of dietary approaches can induce weight loss and improve glycemic control, but differences in remission outcomes are driven largely by adherence and energy deficit rather than macronutrient composition [30]. Low-carbohydrate diets (<130 g/day) improve short-term remission rates and metabolic outcomes compared with higher-carbohydrate diets, although these effects diminish over time and are highly adherence-dependent. Very-low-carbohydrate and ketogenic diets do not reproducibly confer additional benefit when adherence is considered [31].

Mediterranean Diet

Mediterranean-style diets, characterized by high intake of unsaturated fats, fiber, and polyphenols, produce more modest weight loss but confer sustained improvements in glycemic control and cardiovascular risk [11, 32]. Randomized data suggest higher remission rates compared with low-fat diets, although the certainty of evidence remains limited [33]. Intermittent energy restriction, including time-restricted eating and alternate-day fasting, has shown comparable weight loss and remission rates to continuous energy restriction in some studies; however, evidence remains heterogeneous and long-term sustainability is uncertain [28].

Physical Activity: Supportive but Insufficient Alone

Physical activity improves insulin sensitivity independently of weight loss by enhancing skeletal muscle glucose uptake and insulin signaling [34]. Both aerobic and resistance training reduce HbA1c and improve body composition, with combined modalities producing the greatest metabolic benefit [35]. Exercise also reduces visceral adiposity, a major driver of insulin resistance, even without marked weight reduction [34, 36]. Nevertheless, physical activity alone rarely induces remission because it typically does not achieve the degree of weight loss required [36]. Its major contributions are enhancement of weight loss, preservation of lean mass, and improvement of long-term metabolic health when combined with dietary interventions [37].

Bariatric (Metabolic) Surgery and Diabetes Remission

Bariatric surgery remains the most effective intervention currently available for achieving and sustaining remission of T2DM, consistently outperforming lifestyle and medical therapy in both magnitude and durability of glycemic improvement [7, 13].

Mechanisms: Beyond Weight Loss

Although substantial and sustained weight loss is a major driver of remission, bariatric surgery exerts additional weight-independent metabolic effects that contribute to its superior efficacy [38]. Procedures such as Roux-en-Y gastric bypass and sleeve gastrectomy induce rapid post-prandial increases in glucagon-like peptide-1 (GLP-1), enhancing glucose-dependent insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite [38, 39]. These changes contribute to early improvements in glycemia, often preceding significant weight loss [38, 40].

Surgery also alters bile acid metabolism and gut microbiota composition, activating signaling pathways such as FXR and TGR5 that improve insulin sensitivity and energy homeostasis [41, 42]. These mechanisms interact to create a metabolically favorable state that supports sustained glycemic control. In parallel, early caloric restriction and rapid reductions in hepatic fat lead to prompt improvements in hepatic insulin sensitivity, contributing to early normalization of fasting glucose [40].

Comparative Effectiveness

Remission rates vary by procedure, reflecting differences in anatomical and physiological effects (Table 1). Randomized controlled trials consistently demonstrate the superiority of bariatric surgery over non-surgical interventions. In a landmark trial, remission at 3 years was achieved in 40% of patients undergoing Roux-en-Y gastric bypass and 29% following gastric banding, compared with no remission in the intensive lifestyle group [12]. At 5 years, remission persisted in 30% of surgical participants, while remaining negligible in non-surgical controls [13]. Notably, surgical benefit extends beyond traditional eligibility thresholds, with improved glycemic outcomes observed even in individuals with BMI <35 kg/m² [43].

Table 1. Bariatric Procedures and Diabetes Remission Outcomes

ProcedureMechanismTypical Weight LossRemission RateKey AdvantagesLimitations
Roux-en-Y gastric bypass [44-47]Restrictive + hormonal25-35%60-80%High efficacy, durable remissionSurgical complexity, micronutrient deficiency
Sleeve gastrectomy [44,45,48,49]Restrictive + hormonal20-30%50-70%Widely used, lower risk than RYGBSlightly lower remission durability
Biliopancreatic diversion with duodenal switch [50-52]Restrictive + hormonal30-40%70-90%Highest remission ratesHigh complication risk
Adjustable gastric band [53, 54]Restrictive15-20%30-45%Less invasiveLowest efficacy, declining use

Durability and Relapse

Despite high initial remission rates, relapse is common over time. Remission typically peaks within 1-2 years and declines thereafter, particularly in patients with longer diabetes duration or suboptimal weight loss [55, 56]. Relapse should not be interpreted as treatment failure. Even after recurrence of hyperglycemia, patients generally maintain improved glycemic control, reduced medication requirements, and lower cardiometabolic risk compared with pre-intervention states. This supports the conceptualization of bariatric surgery as a disease-modifying intervention rather than a definitive cure [47, 57].

Bariatric Surgery vs Lifestyle Intervention for Diabetes Remission

Direct comparisons reproducibly demonstrate the superior efficacy of bariatric surgery over lifestyle intervention in achieving T2DM remission [13]. Randomized controlled trials show markedly higher remission rates after surgical procedures, with sustained benefits extending beyond 5 years, whereas remission in lifestyle intervention groups is typically modest and less durable [12, 13]. Network meta-analyses estimate that bariatric surgery markedly increases the likelihood of remission compared with non-surgical approaches [58, 59].

These large relative effects should be interpreted cautiously because they are partly driven by low remission rates in control groups; nevertheless, even conservative estimates confirm a substantial absolute benefit of surgery [43, 60, 61].

Magnitude and Durability of Effect

The main distinction between interventions lies not only in remission rates, but in the magnitude and sustainability of metabolic change. Bariatric surgery reliably induces greater and more sustained weight loss, which underpins its superior remission outcomes [50]. In contrast, intensive lifestyle interventions can achieve comparable short-term remission rates under controlled conditions, particularly when large magnitude weight loss is achieved [27]. By comparison, these effects are highly dependent on adherence and typically attenuate over time due to weight regain [24, 62]. Clinically, lifestyle approaches depend on adherence, whereas surgery generates physiological changes that help sustain metabolic outcomes [13].

Mechanistic Distinction

Although both approaches converge on weight loss as a central mechanism, bariatric surgery exerts additional weight-independent effects that are not replicated by lifestyle intervention alone [63]. These include enhanced incretin signalling, altered bile acid metabolism, and changes in gut microbiota, which collectively contribute to improved glucose homeostasis [38, 41]. As a result, surgical intervention often produces more rapid and pronounced glycemic improvements, including early normalisation of fasting glucose prior to substantial weight loss [5].

Patient Selection and Clinical Context

The relative effectiveness of each approach is strongly modified by patient characteristics. Lifestyle interventions are most effective in individuals with shorter diabetes duration, lower baseline HbA1c, and preserved β-cell function profiles associated with greater metabolic reversibility [23]. In contrast, bariatric surgery remains effective across a broader spectrum of disease severity, including patients with longer-standing diabetes or higher treatment burden, although remission rates decline with advancing disease duration [64]. These differences highlight the importance of individualized treatment selection, rather than viewing interventions as competing alternatives [65].

Scalability, Risk, and Implementation

Despite its superior efficacy, bariatric surgery is limited by cost, resource requirements, procedural risk, and restricted access [50]. In contrast, lifestyle interventions are scalable and broadly applicable but constrained by adherence and long-term effectiveness. Thus, the choice between interventions reflects a tradeoff between efficacy and scalability, with surgery offering greater metabolic impact at the cost of invasiveness and accessibility [13].

Predictors of Diabetes Remission

Across both lifestyle and surgical interventions, remission is not random. A consistent set of clinical predictors determines the likelihood of success, largely reflecting the underlying stage of disease and the degree of residual metabolic reversibility [66, 67]. Table 2 presented the major predictors of T2DM remission across lifestyle and surgical interventions

Table 2. Major Predictors of T2DM Remission Across Lifestyle and Surgical Interventions

PredictorFavorable profileMechanistic interpretationClinical implication
Duration of T2DM [21, 36]Short duration, ideally <5-6 yearsGreater preservation of β-cell function and metabolic reversibilitySupports earlier intervention
Baseline HbA1c [68,70]Lower HbA1c at baselineindicates less severe dysglycemia and lower metabolic stressHigher likelihood of remission
Treatment burden [21,66,70]No insulin or lower medication burdenProxy for preserved β-cell reserve and less advanced diseaseUseful pragmatic predictor in routine care
Magnitude of weight loss [57, 64]Greater weight loss, especially ≥10-15%Reduces hepatic and pancreatic fat, improves insulin sensitivityStrongest modifiable determinant
β-cell reserve [36,68,72]Higher C-peptide / preserved insulin secretionEnables maintenance of normoglycemia after interventionCritical for durable remission

Duration of Diabetes

Diabetes duration is one of the strongest and most reproducible predictors of remission. Shorter disease duration is consistently associated across studies with higher remission rates [10,21,68]. This association is biologically plausible: earlier disease is more likely to preserve β-cell function and therefore retain the capacity for metabolic recovery. In contrast, prolonged disease duration likely reflects more advanced and less reversible β-cell failure [56, 69].

Baseline Glycaemia and Treatment Burden

Lower baseline HbA1c and reduced treatment intensity, particularly the absence of insulin therapy, are also strong predictors of remission [68, 70]. These variables serve as pragmatic markers of disease severity. Patients requiring insulin or multiple agents are less likely to achieve remission, not because treatment itself impairs reversibility, but because pharmacologic burden often reflects advanced β-cell dysfunction and reduced metabolic reserve [68, 69].

Magnitude of Weight Loss

The extent of weight loss is the most important modifiable predictor of remission. Evidence from DiRECT showed a strong dose-response relationship, with remission rates rising sharply as weight loss increased [70]. Similar findings have been reported in surgical cohorts, where greater postoperative weight loss is consistently associated with higher remission rates and lower risk of relapse [71]. This is likely consistent with greater reduction in hepatic and pancreatic fat, with corresponding improvements in insulin sensitivity and β-cell function [68, 72].

β-Cell Reserve

Preserved β-cell function is a fundamental requirement for durable remission. Higher fasting or stimulated C-peptide levels and greater insulin secretory capacity independently pre-dict remission following both lifestyle and surgical interventions [68,72,73] Mechanistically, interventions can reduce metabolic stress, but cannot fully restore normoglycemia in the absence of sufficient residual β-cell reserve [39].

Challenges and Limitations

Relapse After Remission

Despite high initial remission rates, particularly following bariatric surgery, relapse is common and represents a main limitation of current remission-oriented strategies [74]. Long-term data demonstrate a progressive decline in remission over time, with a substantial proportion of patients redeveloping hyperglycemia within 5-10 years [56,74,75]. Relapse is not random but is explained by underlying disease biology. Longer pre-intervention diabetes duration, greater baseline treatment burden, and inadequate or unsustained weight loss are consistently associated with loss of remission [64]. These patterns reinforce the concept that remission is biologically constrained, rather than uniformly achievable or permanent.

Relapse should not be equated with treatment failure. Even after recurrence of hyperglycemia, patients typically maintain improved glycemic control, reduced medication requirements, and lower cardiometabolic risk compared with pre-intervention states [74]. This supports framing remission as part of a broader process of disease modification, rather than a binary cure [54, 69].

Limitations of the Evidence Base

Despite substantial progress, important gaps remain in the evidence. Randomized controlled trials with follow-up beyond five years are limited, and those that exist often involve relatively small sample sizes and attrition bias. As a result, long-term durability of remission remains incompletely characterized [12]. Heterogeneity in remission definitions across Magnitude of Weight Loss The extent of weight loss is the most important modifiable predictor of remission. Evidence from DiRECT showed a strong dose-response relationship, with remission rates rising sharply as weight loss increased [70].

Similar findings have been reported in surgical cohorts, where greater postoperative weight loss is consistently associated with higher remission rates and lower risk of relapse [71]. This is likely consistent with greater reduction in hepatic and pancreatic fat, with corresponding improvements in insulin sensitivity and β-cell function [68, 72]. β-Cell Reserve Preserved β-cell function is a fundamental requirement for durable remission.

Higher fasting or stimulated C-peptide levels and greater insulin secretory capacity independently pre-dict remission following both lifestyle and surgical interventions [68,72,73] Mechanistically, interventions can reduce metabolic stress, but cannot fully restore normoglycemia in the absence of sufficient residual β-cell reserve [39]. Challenges and Limitations Relapse After Remission Despite high initial remission rates, particularly following bariatric surgery, relapse is common and represents a main limitation of current remission-oriented strategies [74]. Long-term data demonstrate a progressive decline in remission over time, with a substantial proportion of patients redeveloping hyperglycemia within 5-10 years [56,74,75].

Relapse is not random but is explained by underlying disease biology. Longer pre-intervention diabetes duration, greater baseline treatment burden, and inadequate or unsustained weight loss are consistently associated with loss of remission [64]. These patterns reinforce the concept that remission is biologically constrained, rather than uniformly achievable or permanent. Relapse should not be equated with treatment failure. Even after recurrence of hyperglycemia, patients typically maintain improved glycemic control, reduced medication requirements, and lower cardiometabolic risk compared with pre-intervention states [74]. This supports framing remission as part of a broader process of disease modification, rather than a binary cure [54, 69].

Limitations of the Evidence Base Despite substantial progress, important gaps remain in the evidence. Randomized controlled trials with follow-up beyond five years are limited, and those that exist often involve relatively small sample sizes and attrition bias. As a result, long-term durability of remission remains incompletely characterized [12]. Heterogeneity in remission definitions across Table 2.

Major Predictors of T2DM Remission Across Lifestyle and Surgical Interventions Predictor Favorable profile Mechanistic interpretation Clinical implication Duration of T2DM [21, 36] Short duration, ideally <5-6 years Greater preservation of β-cell function and metabolic reversibility Supports earlier intervention Baseline HbA1c [68,70] Lower HbA1c at baseline indicates less severe dysglycemia and lower metabolic stress Higher likelihood of remission Treatment burden [21,66,70] No insulin or lower medication burden Proxy for preserved β-cell reserve and less advanced disease Useful pragmatic predictor in routine care Magnitude of weight loss [57, 64] Greater weight loss, especially ≥10-15% Reduces hepatic and pancreatic fat, improves insulin sensitivity Strongest modifiable determinant β-cell reserve [36,68,72] Higher C-peptide / preserved insulin secretion Enables maintenance of normoglycemia after intervention Critical for durable remission studies further complicates interpretation.

Differences in glycemic thresholds, duration requirements, and medication use criteria limit comparability and may lead to overestimation of durable remission [2, 47]. In addition, many long-term cohorts include outdated surgical procedures or techniques, reducing generalizability to current practice, particularly with respect to sleeve gastrectomy and modern Roux-en-Y approaches [44,76,77].

Prediction and Uncertainty

Although several predictive models (e.g., DiaRem, ABCD) have been developed, their performance is modest and declines over longer time horizons [78]. Emerging evidence suggests that dynamic factors particularly early weight loss and short-term glycemic response may outperform static baseline models in predicting long-term outcomes [49].

Safety, Cost, and Accessibility

Bariatric surgery, while highly effective, is resource-intensive and not universally accessible. Cost, healthcare infrastructure, and referral pathways limit its availability, particularly in low-resource settings and among socioeconomically disadvantaged populations [50]. Although perioperative risks are relatively low, long-term complications including micronutrient deficiencies, anemia, bone disease, and gastrointestinal disorders require lifelong monitoring [79]. More extensive procedures offer greater metabolic efficacy but at the expense of increased adverse events [80]. These considerations underscore a fundamental tension between efficacy and accessibility, which constrains the population-level impact of surgical interventions [49].

Generalizability and Equity

The populations most likely to achieve remission are individuals with shorter diabetes duration lower HbA1c, and preserved β-cell function are often overrepresented in clinical trials [65]. Consequently, reported remission rates may reflect best-case scenarios rather than real-world populations [81]. Furthermore, many studies exclude individuals with psychiatric comorbidity, complex medical conditions, or socioeconomic barriers, limiting external validity and raising concerns about equity [81, 82]. Addressing these gaps will be essential to ensure that remission-oriented care is not only effective but also equitably delivered [82].

Future Directions and Clinical Implications

The evolving evidence base for T2DM disease reversal necessitates a shift from a binary framework of “remission versus non-remission” toward a more nuanced model centerd on disease modification, durability, and long-term metabolic health [5]. Future research and clinical practice should prioritize strategies that extend beyond short-term glycemic targets to sustained physiological improvement [67].

Refining Patient Selection and Stratification

A primary priority is improving the identification of patients most likely to achieve long-term durability of remission [67]. Current prediction models provide only moderate accuracy and are largely based on static clinical variables. Emerging evidence suggests that dynamic markers, particularly early weight loss and short-term glycemic response may better predict long-term outcomes [67, 77]. Integration of clinical, biochemical, and emerging omics-based markers including C-peptide, metabolomics, and gut microbiome profiles offers a promising avenue for more precise, individualised prediction [5]. Such approaches may enable a transition toward precision metabolic medicine, aligning interventions with underlying disease biology [1].

Optimising Timing of Intervention

The consistent association between shorter diabetes duration and higher remission rates supports earlier, more proactive intervention. Current treatment pathways often delay escalation to intensive or surgical approaches until late disease stages, when reversibility is limited [57]. Reframing T2DM as a potentially reversible condition raises important questions regarding the optimal timing of intervention, including whether bariatric surgery should be considered earlier in the disease course for selected patients. Addressing this will require prospective trials directly comparing early versus delayed intervention strategies [65].

Integrating Therapeutic Approaches

Rather than viewing lifestyle intervention and bariatric surgery as competing strategies, future care models should integrate these approaches within a continuum of metabolic care. Pre- and post-surgical lifestyle optimization, combined with emerging pharmacotherapies, may enhance both remission rates and durability [13, 62]. The increasing availability of highly effective anti-obesity and incretin-based therapies further complicates this landscape, raising important questions regarding sequencing, combination strategies, and long-term comparative effectiveness [51,83,84]. Long-term data beyond 10 years remain limited, with much of the evidence derived from selected cohorts and evolving surgical techniques, restricting generalizability [72, 85].

Major uncertainties include the durability of remission, relapse trajectories, and long-term complications. Increasing emphasis is placed on longitudinal outcomes, including sustained glycemic control, weight maintenance, and patient-centerd measures such as quality of life [47,57,83]. Real-world evidence from registries and routine clinical practice is therefore essential to complement randomized trials and provide a more accurate assessment of long-term effectiveness and safety [26, 71].

Equity, Access, and Health Systems

Despite strong evidence of efficacy, bariatric surgery remains underutilized, particularly among populations with the highest burden of T2DM. Barriers include limited access, inconsistent referral pathways, and health system constraints [51]. Addressing these gaps requires integration of surgical options into standard diabetes care, improved referral processes, policy-level support for funding, and multidisciplinary management. Without these changes, remission-oriented strategies risk exacerbating existing health inequalities rather than reducing them [65, 86].

Conclusion

Remission of T2DM is an achievable and clinically meaningful outcome, challenging the long-standing paradigm of inevitable disease progression. Substantial weight loss remains the dominant determinant of remission, acting through reduction of ectopic fat, restoration of insulin sensitivity, and partial recovery of β-cell function. While lifestyle interventions can induce remission, their long-term effectiveness is limited by challenges in sustaining weight loss. In contrast, bariatric surgery provides the most effective and durable pathway to remission, combining substantial weight loss with weight-independent metabolic effects. However, remission is not universal or permanent.

Relapse is common and reflects underlying disease biology, reinforcing that T2DM is a potentially reversible but biologically constrained condition.

Conflict of Interest

The authors declare that there are no conflicts of interest regarding the publication of this study.

AI Disclosure Statement

During the preparation of this manuscript, the authors used ChatGPT for language editing, grammar improvement, and reference management support. After its use, the authors thoroughly reviewed, verified, and revised all AI-assisted content to ensure accuracy and originality. The authors take full responsibility for the integrity and final content of the published article.

References

  1. Ong KL, Stafford LK, McLaughlin SA, Boyko EJ, Vollset SE, Smith AE, et al. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023 ;402(10397):203-34. ↩
  2. Yu W, Chen Y, Yuan M, Liang A, Kan L, Cai Y, et al. The global burden of earlyonset type 2 diabetes (1990-2050): An age-period-cohort analysis of incidence, disparities, and projections. Diabetes Obes Metab. 2026 ;28(2):1090-104. ↩
  3. Bommer C, Sagalova V, Heesemann E, Manne-Goehler J, Atun R, Bärnighausen T, et al. Global Economic Burden of Diabetes in Adults: Projections From 2015 to 2030. Diabetes Care. 2018 1;41(5):963-70. ↩
  4. Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, et al. Pathophysiology of Type 2 Diabetes Mellitus. Int J Mol Sci. 2020 30;21(17):6275. ↩
  5. De Luca M, Zese M, Bandini G, Chiappetta S, Iossa A, Merola G, et al. Metabolic bariatric surgery as a therapeutic option for patients with type 2 diabetes: A meta-analysis and network meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2023 ;25(8):2362-73. ↩
  6. Juray S, Axen KV, Trasino SE. Remission of Type 2 Diabetes with Very Low-Calorie Diets-A Narrative Review. Nutrients. 2021 18;13(6):2086. ↩
  7. Park YS, Ahn SM, Kim SH, Choi SI, Seo KW, Lee HH, et al. Metabolic Surgery for Obese Type 2 Diabetes: Korean Multicenter Cohort Study. Obes Surg. 2025;35(12):5441-51. ↩
  8. Captieux M, Prigge R, Wild S, Guthrie B. Defining remission of type 2 diabetes in research studies: A systematic scoping review. Basu S, editor. PLOS Med. 2020 28;17(10):e1003396. ↩
  9. Riddle MC, Cefalu WT, Evans PH, Gerstein HC, Nauck MA, Oh WK, et al. Consensus report: definition and interpretation of remission in type 2 diabetes. Diabetologia. 2021 ;64(11):2359-66. ↩
  10. Panunzi S, et al. Determinants of Diabetes Remission and Glycemic Control After Bariatric Surgery. Diabetes Care. 2016;39(1):166-74. ↩
  11. Churuangsuk C, Hall J, Reynolds A, Griffin SJ, Combet E, Lean MEJ. Diets for weight management in adults with type 2 diabetes: an umbrella review of published meta-analyses and systematic review of trials of diets for diabetes remission. Diabetologia. 2022 ;65(1):14-36. ↩
  12. Courcoulas AP, Belle SH, Neiberg RH, Pierson SK, Eagleton JK, Kalarchian MA, et al. Three-Year Outcomes of Bariatric Surgery vs Lifestyle Intervention for Type 2 Diabetes Mellitus Treatment: A Randomized Clinical Trial. JAMA Surg. 2015 1;150(10):931. ↩
  13. Courcoulas AP, Gallagher JW, Neiberg RH, Eagleton EB, DeLany JP, Lang W, et al. Bariatric Surgery vs Lifestyle Intervention for Diabetes Treatment: 5-Year Outcomes From a Randomized Trial. J Clin Endocrinol Metab. 2020;105:866-76. ↩
  14. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia. 2003 1;46(1):3-19. ↩
  15. Yang M, Wei Y, Liu J, Wang Y, Wang G. Contributions of Hepatic Insulin Resistance and Islet β-Cell Dysfunction to the Blood Glucose Spectrum in Newly Diagnosed Type 2 Diabetes Mellitus. Diabetes Metab J. 2025 1;49(4):883-92. ↩
  16. ssen JAMJL. The Pivotal Role of the Western Diet, Hyperinsulinemia, Ectopic Fat, and Diacylglycerol-Mediated Insulin Resistance in Type 2 Diabetes. Int J Mol Sci. 2025 20;26(18):9191. ↩
  17. Xourafa G, Korbmacher M, Roden M. Inter-organ crosstalk during development and progression of type 2 diabetes mellitus. Nat Rev Endocrinol. 2024 ;20(1):27-49. ↩
  18. Janssen JAMJL. Overnutrition, Hyperinsulinemia and Ectopic Fat: It Is Time for a Paradigm Shift in the Management of Type 2 Diabetes. Int J Mol Sci. 2024;25(10):5488. ↩
  19. Cao MJ, Wu WJ, Chen JW, Fang XM, Ren Y, Zhu XW, et al. Quantification of ectopic fat storage in the liver and pancreas using six-point Dixon MRI and its association with insulin sensitivity and β-cell function in patients with central obesity. Eur Radiol. 2023 1;33(12):9213-22. ↩
  20. tin S, Sorokin EP, Thomas EL, Sattar N, Cule M, Bell JD, et al. Estimating the Effect of Liver and Pancreas Volume and Fat Content on Risk of Diabetes: A Mendelian Randomization Study. Diabetes Care. 2022 17;45(2):460-8. ↩
  21. Taylor R. Type 2 diabetes and remission: practical management guided by pathophysiology. J Intern Med. 2021 ;289(6):754-70. ↩
  22. Buse JB, Caprio S, Cefalu WT, Ceriello A, Del Prato S, Inzucchi SE, et al. How Do We Define Cure of Diabetes? Diabetes Care. 2009 1;32(11):2133-5. ↩
  23. Gong JY, Salim A, Magliano DJ, Shaw JE. Impact of eligibility for diabetes remission on response to intensive lifestyle intervention in overweight and obese people with type 2 diabetes: The Look AHEA trial. Diabetes Obes Metab. 2025 ;27(10):5930-7. ↩
  24. Lean MEJ, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomized trial. Lancet Diabetes Endocrinol. 2019 ;7(5):344-55. ↩
  25. Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomized trial. Lancet. 2018 10;391(10120):541-51. ↩
  26. Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. 5-year follow-up of the randomized Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study. Lancet Diabetes Endocrinol. 2024 ;12(4):233-46. ↩
  27. Hocking SL, kovic TP, Lee CMY, Picone TJ, Gudorf KE, Colagiuri S. Intensive Lifestyle Intervention for Remission of Early Type 2 Diabetes in Primary Care in Australia: DiRECT-Aus. Diabetes Care. 2024 1;47(1):66-70. ↩
  28. Valabhji J, Gorton T, Barron E, Safazadeh S, Earnshaw F, Helm C, et al. Early findings from the NHS Type 2 Diabetes Path to Remission Programme: a prospective evaluation of real-world implementation. Lancet Diabetes Endocrinol. 2024 ;12(9):653-63. ↩
  29. Courcoulas A, Patti M, Hu B, Arterburn D, Simonson DC, Gourash W, et al. Long-Term Outcomes of Medical Management vs Bariatric Surgery in Type 2 Diabetes. JAMA. 2024;331 8:654-64. ↩
  30. Rippe JM. Lifestyle Medicine: The Health Promoting Power of Daily Habits and Practices. Am J Lifestyle Med. 2018 ;12(6):499-512. ↩
  31. Goldenberg JZ, Day A, Brinkworth GD, Sato J, Yamada S, Jönsson T, et al. Efficacy and safety of low and very low carbohydrate diets for type 2 diabetes remission: systematic review and meta-analysis of published and unpublished randomized trial data. BMJ. 2021 13;m4743. ↩
  32. Bolla AM, Caretto A, Laurenzi A, Scavini M, Piemonti L. Low-Carb and Ketogenic Diets in Type 1 and Type 2 Diabetes. Nutrients. 2019 26;11(5):962. ↩
  33. Esposito K, Maiorino MI, Petrizzo M, Bellastella G, Giugliano D. The Effects of a Mediterranean Diet on the Need for Diabetes Drugs and Remission of Newly Diagnosed Type 2 Diabetes: Follow-up of a Randomized Trial. Diabetes Care. 2014 1;37(7):1824-30. ↩
  34. Bacchi E, Negri C, Zanolin ME, Milanese C, Faccioli N, Trombetta M, et al. Metabolic Effects of Aerobic Training and Resistance Training in Type 2 Diabetic Subjects. Diabetes Care. 2012 1;35(4):676-82. ↩
  35. Cuff DJ, Meneilly GS, tin A, Ignaszewski A, Tildesley HD, Frohlich JJ. Effective Exercise Modality to Reduce Insulin Resistance in Women With Type 2 Diabetes. Diabetes Care. 2003 1;26(11):2977-82. ↩
  36. Ibañez J, Izquierdo M, Argüelles I, Forga L, Larrión JL, García-Unciti M, et al. Twice-Weekly Progressive Resistance Training reases Abdominal Fat and Improves Insulin Sensitivity in Older Men With Type 2 Diabetes. Diabetes Care. 2005 1;28(3):662-7. ↩
  37. Xin Y, Davies A, Briggs A, McCombie L, Messow CM, Grieve E, et al. Type 2 diabetes remission: 2 year within-trial and lifetime-horizon cost-effectiveness of the Diabetes Remission Clinical Trial (DiRECT)/ Counterweight-Plus weight management program. Diabetologia. 2020 ;63(10):2112-22. ↩
  38. Papamargaritis D, Le Roux CW. Do Gut Hormones Contribute to Weight Loss and Glycaemic Outcomes after Bariatric Surgery? Nutrients. 2021 26;13(3):762. ↩
  39. Fatima F, Hjelmesæth J, Birkeland KI, Gulseth HL, Hertel JK, Svanevik M, et al. Gastrointestinal Hormones and β-Cell Function After Gastric Bypass and Sleeve Gastrectomy: A Randomized Controlled Trial (Oseberg). J Clin Endocrinol Metab. 2022;107(2):e756-66. ↩
  40. Batterham RL, Cummings DE. Mechanisms of Diabetes Improvement Following Bariatric/Metabolic Surgery. Diabetes Care. 2016;39(6):893-901. ↩
  41. Yadav J, Liang T, Qin T, Nathan N, Schwenger KJP, Pickel L, et al. Gut microbiome modified by bariatric surgery improves insulin sensitivity and correlates with increased brown fat activity and energy expenditure. Cell Rep Med. 2023 ;4(5):101051. ↩
  42. Albaugh VL, Banan B, Ajouz H, Abumrad NN, Flynn CR. Bile acids and bariatric surgery. Mol Aspects Med. 2017 ;56:75-89. ↩
  43. Cummings D, Cohen R. Bariatric/Metabolic Surgery to Treat Type 2 Diabetes in Patients With a BMI <35 kg/m2. 2016;39:924-33. ↩
  44. Borgeraas H, Hofsø D, Hertel JK, Hjelmesæth J. Comparison of the effect of Roux-en-Y gastric bypass and sleeve gastrectomy on remission of type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Obes Rev. 2020 ;21(6):e13011. ↩
  45. Castellana M, Procino F, Biacchi E, Zupo R, Lampignano L, Castellana F, et al. Roux-en-Y Gastric Bypass vs Sleeve Gastrectomy for Remission of Type 2 Diabetes. J Clin Endocrinol Metab. 2021;106(3):922-33. ↩
  46. Hage K, Ikemiya K, Ghusn W, Lu L, Kennel KA, et al. Type 2 Diabetes Remission After Roux-en-Y Gastric Bypass: a Multicentered Experience With Long-Term Follow-Up. Surg Obes Relat Dis. 2023;19(12):1339-45. ↩
  47. Yu Z, Li P, Li P, Zhang H, Zhang Y. Meta-analysis of Long-Term Relapse Rate of Type 2 Diabetes Following Initial Remission After Roux-en-Y Gastric Bypass. Obes Surg. 2021 ;31(11):5034-43. ↩
  48. Gambardella C, Mongardini FM, Paolicelli M, Lucido FS, Tolone S, Brusciano L, et al. One Anastomosis Gastric Bypass vs. Sleeve Gastrectomy in the Remission of Type 2 Diabetes Mellitus: A Retrospective Analysis on 3 Years of Follow-Up. J Clin Med. 2024;13(3):899. ↩
  49. Hauge JW, et al. Effect of Gastric Bypass Versus Sleeve Gastrectomy on the Remission of Type 2 Diabetes, Weight Loss, and Cardiovascular Risk Factors at 5 Years (Oseberg): Secondary Outcomes of a Single-Centre, Triple-Blind, Randomized Controlled Trial. Lancet Diabetes Endocrinol. 2025; ↩
  50. Affinati AH, Esfandiari NH, Oral EA, Kraftson AT. Bariatric Surgery in the Treatment of Type 2 Diabetes. Curr Diab Rep. 2019;19(12):156. ↩
  51. Ding L, Fan Y, Li H, Zhang Y, Qi D, Tang S, et al. Comparative Effectiveness of Bariatric Surgeries in Patients with Obesity and Type 2 Diabetes Mellitus: A Network Meta-analysis of Randomized Controlled Trials. Obes Rev. 2020;21(8):e13030. ↩
  52. Sudan R, Jacobs DO. Biliopancreatic diversion with duodenal switch. Surg Clin. 2011;91(6):1281-93. ↩
  53. Dixon JB, O’Brien PE, Playfair J, Chapman L, Schachter LM, Skinner S, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA. 2008;299(3):316-23. ↩
  54. Gulliford MC, Booth HP, Reddy M, Charlton J, Fildes A, Prevost AT, et al. Effect of Contemporary Bariatric Surgical Procedures on Type 2 Diabetes Remission. A Population-Based Matched Cohort Study. Obes Surg. 2016 ;26(10):2308-15. ↩
  55. Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, et al. Metabolic Surgery Versus Conventional Medical Therapy in Patients with Type 2 Diabetes: 10-Year Follow-up of an Open-Label, Single-Centre, Randomized Controlled Trial. Lancet. 2021;397(10271):293-304. ↩
  56. Sjöström L, Peltonen M, Jacobson P, Ahlin S, Andersson-Assarsson J, Anveden Å, et al. Association of Bariatric Surgery With Long-term Remission of Type 2 Diabetes and With Microvascular and Macrovascular Complications. JAMA. 2014 11;311(22):2297. ↩
  57. Aminian A, et al. Late Relapse of Diabetes After Bariatric Surgery: Not Rare, but Not a Failure. Diabetes Care. 2020;43(3):534-40. ↩
  58. Lin C, Yeong TJJ, Lim WH, Ng CH, Yau CE, Chin YH, et al. Comparison of mechanistic pathways of bariatric surgery in patients with diabetes mellitus: A Bayesian network meta-analysis. Obesity. 2022 ;30(7):1380-90. ↩
  59. Mirghani H, Albalawi IA. Metabolic Surgery Versus Usual Care Effects on Diabetes Remission: a Systematic Review and Meta-analysis. Diabetol Metab Syndr. 2023;15(1):31. ↩
  60. Raza Z, Haq MB ul, Imtiaz T, Khokhar MA, Inam A. Short-term outcome of metabolic surgery versus intensive medical therapy among obese type 2 diabetics: a quasi-experimental study. JPMA J Pak Med Assoc. 2025;75 2:186-91. ↩
  61. Zhou X, Zeng C. Diabetes remission of bariatric surgery and nonsurgical treatments in type 2 diabetes patients who failure to meet the criteria for surgery: a systematic review and meta-analysis. BMC Endocr Disord. 2023;23. ↩
  62. Kelly J, Karlsen M, Steinke G. Type 2 Diabetes Remission and Lifestyle Medicine: A Position Statement From the American College of Lifestyle Medicine. Am J Lifestyle Med. 2020;14:406-19. ↩
  63. Kirwan J, Courcoulas A, Cummings D, Goldfine A, Kashyap S, Simonson D, et al. 1226-P: Three Year Outcomes after Metabolic Surgery or Medical/Lifestyle Intervention: The ARMMS-T2D Trial. Diabetes. 2021; ↩
  64. Purnell JQ, Dewey EN, Laferrère B, Selzer F, Flum DR, Mitchell JE, et al. Diabetes Remission Status During Seven-year Follow-up of the Longitudinal Assessment of Bariatric Surgery Study. J Clin Endocrinol Metab. 2021 8;106(3):774-88. ↩
  65. Aminian A, Brethauer SA, Andalib A, Nowacki AS, Jimenez A, Corcelles R, et al. Individualized Metabolic Surgery Score: Procedure Selection Based on Diabetes Severity. Ann Surg. 2017 ;266(4):650-7. ↩
  66. Panunzi S, De Gaetano A, Carnicelli A, Mingrone G. Predictors of Remission of Diabetes Mellitus in Severely Obese Individuals Undergoing Bariatric Surgery: Do BMI or Procedure Choice Matter? A Meta-analysis. Ann Surg. 2015 ;261(3):459-67. ↩
  67. Robert M, Ferrand-Gaillard C, Disse E, Espalieu P, Simon C, Laville M, et al. Predictive Factors of Type 2 Diabetes Remission 1 Year After Bariatric Surgery: Impact of Surgical Techniques. Obes Surg. 2013 ;23(6):770-5. ↩
  68. Wang GF, Yan YX, Xu N, Yin D, Hui Y, Zhang JP, et al. Predictive Factors of Type 2 Diabetes Mellitus Remission Following Bariatric Surgery: a Meta-analysis. Obes Surg. 2015 1;25(2):199-208. ↩
  69. Mateo-Gavira I, Sánchez-Toscano E, o-Ossorio MÁ, Pacheco-García JM, Prada-Oliveira JA, Vílchez-López FJ. Evaluation of Clinical Factors Predictive of Diabetes Remission Following Bariatric Surgery. J Clin Med. 2021 1;10(9):1945. ↩
  70. Thom G, Messow C M., Leslie WS, Barnes AC, Brosnahan N, McCombie L, et al. Predictors of type 2 diabetes remission in the Diabetes Remission Clinical Trial (DiRECT). Diabet Med. 2021 ;38(8):e14395. ↩
  71. Fujihara K, Khin L, Murai K, Yamazaki Y, Tsuruoka K, Yagyuda N, et al. Relationship between the magnitude of body mass index reductions and remission in patients with type 2 diabetes in real world settings: Analysis of nationwide patient registry in Japan ( JDDM 74). Diabetes Obes Metab. 2023 ;25(11):3125-35. ↩
  72. Zhang N, Zhou B, Wang H, Xue X, Huang Y, Wang S, et al. Predictors of diabetes remission after bariatric surgery in patients with type 2 diabetes mellitus duration ≥ 10 years: A retrospective cohort study. Diabetes Res Clin Pract. 2025 ;224:112164. ↩
  73. Casajoana A, Guerrero-Pérez F, García Ruiz De Gordejuela A, Admella V, Sorribas M, Vidal-Alabró A, et al. Role of Gastrointestinal Hormones as a Predictive Factor for Long-Term Diabetes Remission: Randomized Trial Comparing Metabolic Gastric Bypass, Sleeve Gastrectomy, and Greater Curvature Plication. Obes Surg. 2021 ;31(4):1733-44. ↩
  74. Sjöholm K, Svensson PA, Taube M, Jacobson P, Andersson-Assarsson JC, Carlsson LMS, et al. Evaluation of Prediction Models for Type 2 Diabetes Relapse After Post-bariatric Surgery Remission: a Post hoc Analysis of 15-Year Follow-up Data from the Swedish Obese Subjects (SOS) Study. Obes Surg. 2020 ;30(10):3955-60. ↩
  75. Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, et al. Bariatric Surgery Versus Conventional Medical Therapy for Type 2 Diabetes. N Engl J Med. 2012;366:1577-85. ↩
  76. Jiménez A, Casamitjana R, Flores L, Viaplana J, Corcelles R, et al. Long-Term Effects of Sleeve Gastrectomy and Roux-en-Y Gastric Bypass Surgery on Type 2 Diabetes Mellitus in Morbidly Obese Subjects. Ann Surg. 2012; ↩
  77. McTigue KM, Wellman R, Nauman E, Anau J, Coley RY, Odor A, et al. Comparing the 5-Year Diabetes Outcomes of Sleeve Gastrectomy and Gastric Bypass: The National Patient-Centered Clinical Research Network (PCORNet) Bariatric Study. JAMA Surg. 2020 20;155(5):e200087. ↩
  78. Park JY. Prediction of Diabetes Remission after Bariatric or Metabolic Surgery. J Metab Bariatr Surg. 2018;7(1):22. ↩
  79. Ng WW, Rahmatullah IBH, Wahab NBA, Tan CX, Rahim ABA. Prevalence of Anaemia and Related Micronutrient Deficiencies After Bariatric Surgery. J Metab Bariatr Surg. 2025;14(3):210. ↩
  80. Gasmi A, Bjørklund G, Mujawdiya PK, Semenova Y, Dosa A, Piscopo S, et al. Dietary supplements and bariatric surgery. Crit Rev Food Sci Nutr. 2023 3;63(25):7477-88. ↩
  81. Pereira S, Guimarães M, Monteiro M. Towards precision medicine in bariatric surgery prescription. Rev Endocr Metab Disord. 2023;24:961-77. ↩
  82. Soliman A, Saleem HM eldin, Meligi AAHE, Naguib M, Mohamed RS, Abdelaziz GR, et al. Metabolic/bariatric surgery optimization: a position statement by Arabic association for the study of diabetes and metabolism (AASD). Diabetol Metab Syndr. 2025;17. ↩
  83. Arterburn DE, Bogart A, Sherwood NE, Sidney S, Coleman KJ, Haneuse S, et al. A Multisite Study of Long-term Remission and Relapse of Type 2 Diabetes Mellitus Following Gastric Bypass. Obes Surg. 2013 ;23(1):93-102. ↩
  84. Dicker D, Yahalom R, Comaneshter DS, Vinker S. Long-Term Outcomes of Three Types of Bariatric Surgery on Obesity and Type 2 Diabetes Control and Remission. Obes Surg. 2016 ;26(8):1814-20. ↩
  85. Vitiello A, Abu-Abeid A, Dayan D, Berardi G, Musella M. Long-Term Results of Laparoscopic Sleeve Gastrectomy: a Review of Studies Reporting 10+ Years Outcomes. Obes Surg. 2023 ;33(11):3565-70. ↩
  86. Brethauer SA, Aminian A, Romero-Talamás H, Batayyah E, Mackey J, Kennedy L, et al. Can Diabetes Be Surgically Cured? Long-Term Metabolic Effects of Bariatric Surgery in Obese Patients with Type 2 Diabetes Mellitus. Ann Surg. 2013 ;258(4):628-37. ↩